-- Advances 5x30 strategy by expanding pipeline with a highly complementary asset that has the potential to provide several days of pain control -- -- Phase 2 program for AMT-143 expected to begin in 2026 -- BRISBANE, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced an exclusive worldwide license and collaboration agreement with AmacaTh ...

BRISBANE, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced that it will report its third quarter financial results after the close of the U.S. markets on Thursday November 6, 2025. Following the release, the company will host a live conference call and webcast at 4:30 p.m. ET. For listeners who wish to participate in the question and ans ...

-- Data demonstrates sustained clinical improvements in pain, stiffness and function for up to 156 weeks following a single administration of PCRX-201 -- BRISBANE, Calif., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies to transform the lives of patients, today announced updated three-year results and a new subset analyses demonstrating sustained efficacy and safety across all patient subgroups, including ...

核心事件概述 - 公司收到来自齐鲁制药（海南）有限公司的第四段认证通知函，该函针对公司核心产品EXPAREL的仿制药申请 [1] - 齐鲁制药已向美国FDA提交了简略新药申请，寻求批准EXPAREL的仿制等效药 [1] - 公司声称将积极维护其知识产权，并在收到通知后的45天内有权提起诉讼，诉讼将触发对ANDA批准的30个月自动暂停期 [4] 专利争议详情 - 齐鲁制药在PIV通知中指控，与EXPAREL相关的18项FDA橙皮书所列专利无效、不可执行和/或不构成侵权 [2] - 涉及的18项专利属于两个不同的专利家族，第一个专利家族到期日为2041年1月22日，第二个专利家族到期日为2044年7月2日 [3] 公司产品与业务 - 公司是提供创新非阿片类疼痛疗法的行业领导者，拥有三款商业阶段非阿片类治疗产品：EXPAREL、ZILRETTA和iovera [5] - EXPAREL是首个也是唯一一个可在围手术期或术后使用的多囊脂质体局部麻醉剂，单次给药可将阿片类药物消耗量降低高达78% [6] - 公司正在推进PCRX-201（一种新型局部给药的基因疗法）的开发，该疗法有潜力治疗骨关节炎等大型常见疾病 [5] 产品安全信息 - EXPAREL禁用于产科宫颈旁阻滞麻醉，其常见副作用包括恶心、便秘和呕吐等 [7] - 该产品可能导致暂时性感觉和/或肌肉运动功能丧失，效果可持续长达5天，不建议用于6岁以下儿童伤口浸润、18岁以下儿童神经阻滞或孕妇 [7][8]

-- Findings Presented at AMCP Nexus 2025 Annual Meeting -- BRISBANE, Calif., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies to transform the lives of patients, today announced real-world evidence evaluating the clinical effectiveness and economic benefits of EXPAREL® (bupivacaine liposome injectable suspension) will be presented at the AMCP Nexus 2025 Annual Meeting taking place October 27–30 in National ...

BRISBANE, Calif., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients today reported it has received a Paragraph IV Certification Notice Letter (PIV Notice) from The WhiteOak Group, a subsidiary of a small private Chinese company. WhiteOak has filed an Abbreviated New Drug Application, or ANDA, with the FDA for a product claiming to be a generic of EXPAREL. Neither ...

-- Poster to be presented at American College of Rheumatology Convergence 2025 – BRISBANE, Calif., Oct. 20, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced that new data from its Phase 1 clinical trial evaluating PCRX-201 (enekinragene inzadenovec), a novel gene therapy candidate for osteoarthritis of the knee, will be presented at the American College ...

SASKATOON, Saskatchewan, Oct. 17, 2025 (GLOBE NEWSWIRE) -- PHARMACORP RX INC. (“PharmaCorp” or the “Corporation”) (TSXV:PCRX) is pleased to announce that it has filed its Final Short Form Base Shelf Prospectus dated October 14, 2025 (the “Prospectus”) with the securities commissions in each of the provinces of Canada, other than Quebec. The Prospectus allows the Corporation to ‎qualify the distribution by way of prospectus in Canada of up to $100 million of common shares, preferred ‎shares, warrants, debt s ...

SASKATOON, Saskatchewan, Oct. 10, 2025 (GLOBE NEWSWIRE) -- PHARMACORP RX INC. (“PharmaCorp” or the “Corporation”) (TSXV: PCRX) has restated and refiled its financial statements for the interim period ended June 30, 2025 (the “Amended Q2 2025 Statements”) as well as the corresponding management's discussion and analysis under PharmaCorp’s profile on www.sedarplus.ca . In conjunction with a review completed by the Corporation’s Auditor, it was determined to make certain accounting adjustments to the Amended Q ...

收购交易概述 - 公司已完成对三家社区药房业务的收购，其中两家位于加拿大西部，一家位于加拿大东部 [1] 西部收购详情 - 加拿大西部的两项收购总价为340万美元，其中75%以现金支付，25%通过发行公司普通股支付 [2] - 普通股的发行价格依据多伦多证券交易所创业板在收盘前第三个营业日结束的十个交易日内成交量加权平均交易价格确定 [2] - 其中一项收购包含相关土地和建筑物 [2] 东部收购详情 - 加拿大东部的单项收购价格为530万美元，收购资金来源于公司现金及信贷额度下的可用资金 [3] - 所有收购交易均未支付中介费用 [3] 战略与管理层评论 - 管理层表示此次交易反映了公司既定增长战略的持续势头以及与PharmaChoice Canada战略联盟的实力 [4] - 通过收购加强了在加拿大西部和东部的全国布局，旨在保持独立药房的传承并为患者提供持续的护理服务 [4] - 公司计划在未来几个月继续积极寻求收购机会 [4] 公司背景与战略 - 收购完成后，公司目前共运营七家PharmaChoice Canada品牌药房 [5] - 公司将根据与PharmaChoice Canada的战略联盟协议，继续收购该品牌药房，并将收购的非品牌药房转为该品牌运营 [5] - 公司公开鼓励并欢迎考虑交接或出售的药房业主进行接洽 [6]